Human Oncology & Pathogenesis Program
The Emily Cheng Lab
Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS, Cheng EH. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer. 2022 Feb 3. doi: 10.1038/s43018-021-00316-3. Epub ahead of print.
Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021 Sep 13;39(9):1245-1261.e6. doi: 10.1016/j.ccell.2021.07.006. Epub 2021 Aug 12. PMCID: PMC8440494.
Ren D, Tu H, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.
Kim H, Rafiuddin-Shah M, Tu HC, Jeffers J, Zambetti GP, Hsieh JJD, Cheng EHY. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006 Dec;8(12):1348-58. Epub 2006 Nov 19.
Emily H. Cheng, MD, PhD
Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program
- Physician-scientist Emily Cheng focuses on the molecular mechanisms of cell death and their implications in tumorigenesis and cancer therapy, with primary emphasis on lung and kidney cancers.
- MD, Taipei Medical University
- PhD, Johns Hopkins University School of Medicine
- Distinguished Investigator Award, Washington University School of Medicine (2010)
- Searle Scholar Award (2005)
- Howard Temin Award, National Cancer Institute (2003)
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Emily H. Cheng discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.